JAZZ

#794
Jazz Pharmaceuticals, Inc.
199.5850 USD
+2.19%
版块: 医疗保健
基础: USD
利润货币: USD
日范围
199.3200
199.6500
年范围
128.8000
200.2400
日变化
+2.19%
每月变动
+11.05%
6个月变化
+42.56%
年变化
+42.56%
前一天收盘价
195.3100
开盘价
199.5000
买价
卖价
最低价
199.3200
High
199.6500
交易量
97
展开完整图表

Financials

概览 声明 统计
每季度 年度
  • Market Capitalization 12.2865 B
  • Employee 2 890
  • Founded 2003
  • CEO Bruce C Cozadd
  • Website www.jazzpharmaceuticals.com
  • Headquarter Ireland
  • FIGI N/A
  • Industry Technology
总收入
净利润
每股基本收益（基本 EPS）
总债务
自由现金流
现金及现金等价物
市盈率
-29.11
市销率
2.43

Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc is an American global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland. One of the company's considerable products is the United States Food and Drug Administration approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid. In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness in narcolepsy as well as obstructive sleep apnea. In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals. In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use. The company is also a member of the Pharmaceutical Research and Manufacturers of America.

新闻